May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Photodynamic Therapy With Verteporfin for Chronic Central Serous Chorioretinopathy
Author Affiliations & Notes
  • F. Boscia
    Otolaryngology/Ophthalmology, Universita di Bari, Bari, Italy
  • N. Cardascia
    Otolaryngology/Ophthalmology, Universita di Bari, Bari, Italy
  • C. Furino
    Otolaryngology/Ophthalmology, Universita di Bari, Bari, Italy
  • C. Sborgia
    Otolaryngology/Ophthalmology, Universita di Bari, Bari, Italy
  • Footnotes
    Commercial Relationships  F. Boscia, None; N. Cardascia, None; C. Furino, None; C. Sborgia, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4066. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. Boscia, N. Cardascia, C. Furino, C. Sborgia; Photodynamic Therapy With Verteporfin for Chronic Central Serous Chorioretinopathy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4066. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the efficacy of photodynamic therapy (PDT) with verteporfin for chronic central serous chorioretinopathy (CCSC). Methods: Eleven eyes of 11 patients (age: 58±2.9 years, 8 males, 3 female) with CCSC and pigment epithelium detachment (PED) revealed by fluorescein angiography (FA), indocyanine–green angiography (ICG–A) and optical coherence tomography (OCT) underwent PDT with verteporfin following TAP protocol. The treatment covered the PED and focal areas of hyperpermeability. Functional and anatomical outcomes were observed at 1, 3, 6 and 12 months after the treatment by best corrected visual acuity (BCVA) assessment using ETDRS chart, FA, ICG–A and OCT. Results: After 12 months, mean visual acuity remained stable, varying from 0.22 ±0.09 to 0.22±0.18 LogMAR (p=0.97). At the end of the follow up, BCVA remained stable in 4 eyes, improved in 6 and decreased in 1 eye. PED and focal areas of hyperpermeability disappeared after 1 month in 10 eyes, and remained invaried at the end of the follow up. One eye developed a choroidal neovascularization (CNV) which was successfully treated with 2 courses of PDT. Conclusions: Photodynamic therapy with verteporfin appears to have a beneficial effect in patients with CCSC by reducing fluid leakage, subretinal fluid accumulation, and serous detachment with resultant improvement in vision. Still some reservation exist as the possible stimulation of CNV.

Keywords: photodynamic therapy • macula/fovea • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×